ea0041ep907 | Pituitary - Clinical | ECE2016
Tasdelen Mustafa Rasid
, Durmaz Senay Arikan
, Yildirim Nesligul
, Koc Eyup
Introduction and aim: Cabergoline, a long-lasting dopamine-agonist, is generally considered to be the safety drug for the treatment of prolactinoma. But, use of long time and high dose cabergoline may be a cause of cardiac valvulopathy in patient with prolactinoma. In present study, we aim to determine serum N-terminal probrain natriuretic peptide levels in patients with prolactinoma who were treated with cabergoline.Materials and methods: Thirty patient...